According to a 2021 study, out of the 8.9 million adults who take medication for major depressive disorder, approximately 2.8 million (30.9%) have treatment-resistant depression (TRD). Patients who have not had a positive response to two or more antidepressants from different classes can be considered as having treatment-resistant depression.

If you have TRD and have not found relief, there is hope.

Spravato is transforming the landscape for those with treatment-resistant depression, providing a beacon of hope where other therapies have fallen short. With its innovative approach, many are finding relief and a path toward brighter days.

In a clinical trial, after four weeks of treatment, about 70% of patients had at least a 50% reduction in symptoms, and about 50% achieved complete remission from depressive symptoms.

In a clinical trial, after four weeks of treatment, about 70% of patients had at least a 50% reduction in symptoms, and about 50% achieved complete remission from depressive symptoms.